Skip to search formSkip to main contentSkip to account menu

Trastuzumab VC-seco-DUBA

Known as: ADC SYD985, Antibody-drug Conjugate SYD985, SYD985 
An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
PURPOSE OF REVIEW Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting… 
2020
2020
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
While the global cancer burden is still high with 10 million people being diagnosed with cancer and 6 million cancer-related… 
2017
2017
Abstract P6-12-02: SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer
Background: SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and a cleavable linker-duocarmycin (vc… 
2015
2015
333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
2015
2015
Abstract 2461: SYD985, a novel HER2-targeting antibody-drug conjugate, shows strong antitumor activity in primary USC cell lines with low (1+) and moderate (2+) HER2/Neu expression
Introduction: Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer which carries an extremely poor… 
2015
2015
Abstract P4-15-14: Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression
SYD985 is a novel anti-HER2 antibody-drug conjugate (ADC) in development for breast cancer. The ADC consists of three parts: i… 
2015
2015
Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, Synthon9s proprietary cleavable linker-duocarmycin payload… 
2014
2014
Abstract 2651: Impressive efficacy and safety profile of a novel generation duocarmycin-based HER2-targeting ADC
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA We have built a linker-drug platform based on a cleavable… 
2014
2014
Abstract 2652:In vitroandin vivoantitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1
SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon9s proprietary cleavable linker-duocarmycin payload. The… 
2003
2003
Vlijanie vnutrennejejj zaboloni na khimicheskijj sostav drevesiny chereshhatogo duba (Quercus petrea Liebl)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)